Burton S. Sader, R. K. Flamm, J. M. Streit, R. N. Jones; JMI Lab., Inc., N Liberty, IA. K. Flamm D. Brown, M. M. Traczewski; Clinical Microbiol. Inst., Inc., Wilsonville, OR. S. Sader, M. Castanheira, R. K. Flamm, R. N. Jones; JMI Lab., Inc., N Liberty, I

48 SCIENTIFIC SESSIONS September 9-12 | D-178 Comparative Evaluation of 8 Commercial Multiplex PCR Kits for the Diagnosis of Respiratory Infection M. Lardeux 1 , S. Pillet 1 , J. Dina 2 , F. Grattard 1 , P. O. Verhoeven 1 , J. Legoff 3 , A. Vabret 2 , B. Pozzetto 1 ; 1 Univ. Hosp. of Saint Etienne, Saint Etienne, France, 2 Univ. Hosp. of Caen, Caen, France, 3 Saint-Louis Hosp., Paris, France. D-179 Prevalence of Respiratory Viruses in the Community of Northern Saxony and Saxony-Anhalt, Germany

N. H. Zaiss, M. Kunze, G. Ackermann; Alphaomega Labor, Delitzsch, Germany.

D-180 Prognostic Value of Serum Albumin Levels at Admission in Hospitalized Adults with Community-Acquired Pneumonia D. Viasus, C. Garcia-Vidal, J. Dorca, F. Gudiol, J. Carratalà; Hosp. de Bell- vitge - IDIBELL, Univ. of Barcelona, Barcelona, Spain. D-181 Prevalence of Bacterial Otitis Media and Antimicrobial Sus- ceptibility Pattern in Ethiopia

D. S. Fentaw

1 , Y. Bekele 2 , T. Getachew 3 ; 1 UIO, Oslo, Norway, 2 AHRI, Ad- dis Ababa, Ethiopia, 3 EHNRI, Addis Ababa, Ethiopia. ------------------------------------------------------------------------ 014 D Poster Session Serologic Methods for Detection of Infectious Diseases Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: D-182 Optimal Cutoff Value of Serum Adenosine Deaminase Activ- ity for Diagnosing Acute Scrub Typhus

J. Lee

1 , J. Cho 2 , E. Choi 3 ; 1 Inst. of Wonkwang Med. Sci., Iksan, Korea, Re- public of, 2 Wonkwang Univ. Hosp., Iksan, Korea, Republic of, 3 Mirawomen Pedriatric Hosp., Iksan, Korea, Republic of. D-183 Diagnostic Cutoffs for Increases and Absolute Values of Im- munoglobulin G Antibodies against Pertussis Toxin S. C. de Greeff 1 , P. Teunis 1 , H. E. de Melker 1 , F. R. Mooi 1 , D. Notermans 1 , B. Elvers 1 , J. F. P. Schellekens 2 ; 1 Natl. Inst. for Publ. Hlth. and the Environ- ment, Bilthoven, Netherlands, 2 Lab. for Infectious Diseases, Groningen, Netherlands. D-184 A Comparison of Three Anti-HEV IgG EIA Screening Kits and One Confirmatory Immunodot Assay in Blood Donor Samples in Switzerland A. Schnegg 1 , P. Bürgisser 2 , C. André 2 , A. Kenfak-Foguena 2 , G. Canellini 3 , D. Moradpour 2 , M. Cavassini 2 , K. E. Darling 2 ; 1 Univ. of Lausanne, Laus- anne, Switzerland, 2 Ctr. Hosp. Univ. Vaudois, Univ. of Lausanne, Lausanne, Switzerland, 3 Service Régional Vaudois de Transfusion Sanguine, Epalinges, Switzerland. D-185 Optimizing the Positive Predictive Value of the Focus HSV-2 ELISA in Hepatitis C Infected Veterans at the Jackson VAMC

M. Burton

1 , E. Swiatlo 1 , I. Sunesara 2 , A. Penman 2 , C. Young 1 , E. W. Hook, III 3 ; 1 G.V. Sonny Montgomery VAMC, Jackson, 2 Univ. of Mississippi Med. Ctr., Jackson, 3 Univ. of Alabama, Birmingham, AL. ---------------------------------------------------------------------------------- 015 E Poster Session In Vitro Activity of Beta-Lactamase Inhibitor Combinations Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: E-186 Antimicrobial Activity of Ceftaroline-Avibactam CPA Tested against Contemporary Clinical Isolates from USA Medical Centers 2011

H. S. Sader, R. K. Flamm, J. M. Streit, R. N. Jones; JMI Lab., Inc., N Liberty, IA.

E-187 Avibactam Reverts the Ceftazidime CAZ MIC 90 of a Recent Set of European Clinical Isolates of Gram-Negative Bacteria Back to the Epidemiological Cut-Off Value ECOFF

R. K. Flamm

1 , W. W. Nichols 2 , H. S. Sader 1 , R. N. Jones 1 ; 1 JMI Lab., N Liberty, IA, 2 AstraZeneca Pharmaceuticals LP, Waltham, MA. E-188 Quality Control Parameters for Ceftaroline-Avibactam Disk Diffusion, Anaerobic Broth Microdilution and Agar Dilution Quality Control

S. D. Brown, M. M. Traczewski; Clinical Microbiol. Inst., Inc., Wilsonville, OR.

E-189 Antimicrobial Spectrum and Potency of Ceftaroline-Avibactam Tested against ESBL-Phenotype and Carbapenem-Resistant Enterobacteriaceae Collected from USA Hospitals 2009-2011

H. S. Sader, M. Castanheira, R. K. Flamm, R. N. Jones; JMI Lab., Inc., N Liberty, IA.

E-190 In Vitro Activity of Ceftazidime Alone and in Combination with Avibactam against Resistant Pseudomonas aeruginosa and Enterobacteriaceae

M. J. B. Melchers

1 , C. H. van Mil 2 , J. W. Mouton 1 ; 1 Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 2 Canisius Wilhelmina Hosp., Nijmegen, Netherlands. E-191 In Vitro Activity of Ceftaroline-Avibactam against Frequently Isolated Bacterial Pathogens from Patients in Canadian Hospitals

J. Karlowsky